Tumor microenvironment assessment-based signatures for predicting response to immunotherapy in non-small cell lung cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new biomarker, IKCscore, predicts response to cancer immunotherapy in non-small cell lung cancer (NSCLC). This score identifies patients likely to benefit from immunotherapy, guiding personalized treatment strategies.
Area Of Science
- Oncology
- Immunology
- Genomics
Background
- Immunotherapy has revolutionized non-small cell lung cancer (NSCLC) treatment.
- However, not all patients achieve lasting benefits from immunotherapy.
- Predictive biomarkers are crucial for identifying suitable candidates for immunotherapy.
Purpose Of The Study
- To develop and validate a novel biomarker for predicting immunotherapy response in NSCLC.
- To assess the biomarker's performance across diverse cancer types and patient cohorts.
Main Methods
- Retrospective analysis of tumor tissues from 65 advanced NSCLC patients.
- Transcriptomic and genomic analysis coupled with single-sample gene set enrichment analysis.
- Construction and validation of the IKCscore using multiple public datasets (N=892).
Main Results
- The IKCscore effectively predicts response to immunotherapy in NSCLC.
- High IKCscore correlates with an inflammatory tumor microenvironment and increased T cell receptor diversity.
- The biomarker's predictive capability was validated across various cancer types.
Conclusions
- The IKCscore is a robust biomarker for predicting immunotherapy efficacy in NSCLC.
- It shows promise for guiding personalized therapeutic strategies, including combination therapies.
- IKCscore offers valuable insights into patient selection for immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
